Jefferies initiated coverage of Guardian Pharmacy (GRDN) with a Buy rating and $44 price target The company is positioned post annual 12%-16% EBITDA growth given the secular growth in the senior housing space, the analyst tells investors in a research note. The firm says Guardian’s “best-in-class execution” is driving market share gains and operating efficiencies, while its accretive acquisitions also can bring “positive earnings surprises.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Buy Rating on Guardian Backed by Sustainable Mid‑Teens EBITDA Growth, Market Share Gains, and Accretive Expansion Strategy
- Guardian Pharmacy Services Ends Controlled Company Status on NYSE
- Guardian Pharmacy 6M share Spot Secondary priced at $31.00
- Guardian Pharmacy prices 6M shares at $31.00 in upsized public offering
- Guardian Pharmacy secondary offering; price range $30.60-$31.60